Immupharma

IMM · AIM · Health Care · mcap £24m · 3.7p

EV: £22.1m
EV / EBIT: –
Net cash: £696k
FCF yield: -8.1%
Revenue: £0k
Share price 1y: −69%
Insiders 12m: no deals
Next report: around 26 May

Beta Briefing, track record and signals & risks are not ready for Immupharma yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 Placing of 30% of the market value Placing of 33% of the market value Lanstead Capital Investors LP selling down Placing of 23% of the market value

Closed · 4

Dilutive fundraisePlacing of 30% of the market value completed · 15 Sep 2026 – 15 Oct 2026 Dilutive fundraisePlacing of 33% of the market value completed · 17 Mar 2026 – 26 Jun 2026 −54% OverhangLanstead Capital Investors LP selling down holder sold out · 27 May 2025 – 4 Nov 2025 +156% Dilutive fundraisePlacing of 23% of the market value completed · 19 May 2025 – 18 Jun 2025 +198%

Company filings. Not investment advice.